ScholarIQanswers from OpenAlex
NIHR Bristol Cardiovascular Biomedical Research Unit
InstitutionResearch output, impact & collaborations
NIHR Bristol Cardiovascular Biomedical Research Unit is a institution indexed in ScholarIQ from OpenAlex.
What is known about NIHR Bristol Cardiovascular Biomedical Research Unit?
ScholarIQrecord summary
NIHR Bristol Cardiovascular Biomedical Research Unit is a research organisation in Bristol, GB. OpenAlex records 2,190 works and 235,684 citations for it. 376 researchers list it as their most recent affiliation.
How many works does NIHR Bristol Cardiovascular Biomedical Research Unit have?
ScholarIQindexed works
NIHR Bristol Cardiovascular Biomedical Research Unit has 2,190 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does NIHR Bristol Cardiovascular Biomedical Research Unit have?
ScholarIQcitation count
NIHR Bristol Cardiovascular Biomedical Research Unit has 235,684 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at NIHR Bristol Cardiovascular Biomedical Research Unit?
ScholarIQresearcher count
NIHR Bristol Cardiovascular Biomedical Research Unit has 376 researchers in the ScholarIQ index.
What is the average h-index at NIHR Bristol Cardiovascular Biomedical Research Unit?
ScholarIQavg h-index
NIHR Bristol Cardiovascular Biomedical Research Unit has an average h-index of 58 in OpenAlex.
What is the ROR of NIHR Bristol Cardiovascular Biomedical Research Unit?
ScholarIQror
The ROR for NIHR Bristol Cardiovascular Biomedical Research Unit is on the source record.
What is the OpenAlex record for NIHR Bristol Cardiovascular Biomedical Research Unit?
ScholarIQopenalex
The OpenAlex for NIHR Bristol Cardiovascular Biomedical Research Unit is on the source record.
Who are the most-cited researchers behind NIHR Bristol Cardiovascular Biomedical Research Unit?
ScholarIQtop researchers by citations
What are the most-cited papers on NIHR Bristol Cardiovascular Biomedical Research Unit?
ScholarIQmost cited works
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan, Paul J. Ross, Yuk Ting, Arvind Arora, Stephen Falk, Roopinder Gillmore, Jonathan Wadsley, Kinnari Patel, Alan Anthoney, Anthony Maraveyas, Timothy Iveson, Justin S. Waters, Claire Hobbs, Safia Barber, W. David J. Ryder, John Ramage, Linda Davies, John Bridgewater, Juan W. Valle
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
Harpreet Wasan, Peter Gibbs, Navesh Sharma, Julien Taı̈eb, Volker Heinemann, Jens Ricke, Marc Peeters, Michael Findlay, Andrew Weaver, Jamie Mills, Charles Wilson, Richard Adams, Anne Francis, Joanna Moschandreas, Pradeep S. Virdee, Peter Dutton, Sharon Love, Val Gebski, Alastair Gray, Richard Adams, Andrew Bateman, Claire Blesing, Ewan Brown, Ian Chau, Sebastian Cummins, David Cunningham, Stephen Falk, Maher Hadaki, Marcia Hall, Tamas Hickish, Joanne Hornbuckle, F. Lofts, Sarah Lowndes, Astrid Mayer, Matthew S. Metcalfe, Gary Middleton, Jamie Mills, Amir Montazeri, R. Muirhead, Andreas Polychronis, Colin Purcell, Paul J. Ross, Ricky A. Sharma, Liz Sherwin, David Smith, Rubin Soomal, Daniel Swinson, Axel Walther, Harpreet Wasan, Andrew Weaver, Charles Wilson, Greg Wilson, Pradip Amin, Bruna Angelelli, Jacques Balosso, Alex Beny, Daniel Bloomgarden, Evelyn Boucher, Michael D. Brown, Harald-Robert Bruch, James Bui, Matthew Burge, Giuseppe Cardaci, James Carlisle, Seungjean Chai, Yi‐Jen Chen, P. Chevallier, Michael Chuong, Stephen Clarke, Andrew L. Coveler, M Craninx, Thierry Delanoit, Amélie Deleporte, Paul Eliadis, Francis Facchini, Thomas W. Ferguson, Michel Ferrante, Michael Findlay, Gary Frenette, Jacob Frick, Vinod Ganju, Michael Garofalo, Karen Geboes, Gerald Gehbauer, Benjamin George, Ravit Geva, Peter Gibbs, Melita A. Gordon, Kate Gregory, Seza A. Güleç, James Hannigan, Guy van Hazel, Norman Heching, Volker Heinemann, Thomas Helmberger, Alain Hendlisz, Koen Hendrickx, Matthew P. Holtzman, Richard Isaacs, Christopher Jackson
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial
John V. Reynolds, Shaun R. Preston, Brian Patrick O’Neill, Maeve A. Lowery, Lene Bæksgaard, T. Crosby, Moya Cunningham, Sinéad Cuffe, Gareth Griffiths, Imelda Parker, Signe Lenora Risumlund, Rajarshi Roy, Stephen Falk, George B. Hanna, Frederick R. Bartlett, Alberto Alvarez‐Iglesias, Michael Patrick Achiam, Magnus Nilsson, Guillaume Piessen, Narayanasamy Ravi, Dermot O’Toole, Ciarán Johnston, Raymond S McDermott, Richard Turkington, Shajahan Wahed, Sharmila Sothi, Hugo Ford, Martin Wadley, Derek G. Power, Somnath Mukherjee, Carys Morgan, Simon L. Parsons, Neel Bhuva, Sorcha Campbell, Liam Grogan, Greg Leonard, Andrew Bateman, Catherine Mitchell, Séamus O’Reilly, Eibhlin Mulroe, Olivia McLoughlin, Anna Shevlin, Aoife M. Shannon, Jacinta Marron, Marc Nolan, Grace Burch, Michelle Costello, Daniel E. Griffiths, Kelly Cozens, Emma Foley, Claire L. Donohoe, Catherine O’Farrell, Jennifer E. Moore, Jacintha O’Sullivan
How much of the research on NIHR Bristol Cardiovascular Biomedical Research Unit is open access?
ScholarIQopen access share
100%OPEN ACCESS